IR correlates with more severe retinopathy in young adults with Type 1 DM. This is the first description of a correlation between IR and maculopathy in Type 1 DM, warranting further evaluation. Prospective studies examining whether reducing IR can improve microvascular complications are required (Diabetes Research and Clinical Practice)
Diabetes News
Tag: retinopathy
Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks
Patients with proliferative diabetic retinopathy who were treated with intravitreal aflibercept had an improved outcome at 1 year compared with those treated with PRP standard care (Lancet)
Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes
Our model for establishing an individualized schedule for retinopathy screening on the basis of the patient’s current state of retinopathy and glycated hemoglobin level reduced the frequency of eye examinations without delaying the diagnosis of clinically significant disease (NEJM)
The English National Screening Programme for diabetic retinopathy 2003–2016
The benefit of the programme is that, in England, diabetic retinopathy/maculopathy is no longer the leading cause of certifiable blindness in the working age group (Acta Diabetologica)
Diabetic Retinopathy
A Position Statement by the American Diabetes Association (Diabetes Care)
Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs
In this evaluation of retinal fundus photographs from adults with diabetes, an algorithm based on deep machine learning had high sensitivity and specificity for detecting referable diabetic retinopathy (JAMA)
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy A Randomized Clinical Trial
Among eyes with proliferative diabetic retinopathy, treatment with ranibizumab resulted in visual acuity that was noninferior to (not worse than) PRP treatment at 2 years. Although longer-term follow-up is needed, ranibizumab may be a reasonable treatment alternative, at least through 2 years, for patients with proliferative diabetic retinopathy (JAMA)
Cross Talk between Lipid Metabolism and Inflammatory Markers in Patients with Diabetic Retinopathy
It seems that there is a link between metabolic and inflammatory markers. Apo-B/Apo-A ratio should be evaluated as a reliable risk factor for PDR and CSME, while the role of increased systemic TNF-α and VEGF should be explored in CSME (Journal of Diabetes Research)
Significance of the antiangiogenic mechanisms of thalidomide in the therapy of diabetic retinopathy
Amongst several antiangiogenic agents, thalidomide holds a reputable position due to its effectiveness in terminating angiogenesis during various pathological conditions. This review focuses on the diverse molecular mechanisms proposed to explain the antiangiogenic properties of thalidomide and their applicability in diabetic retinopathy (Vascular Pharmacology)
Combined Methods for Diabetic Retinopathy Screening, Using Retina Photographs and Tear Fluid Proteomics Biomarkers
As the two different types of data represent independent and complementary information on the outcome, the combined model resulted in a reliable screening method that is comparable to the requirements of DR screening programs applied in clinical routine (Journal of Diabetes Research)
Diabetic Retinopathy in Pregnancy: A Population-Based Study of Women with Pregestational Diabetes
This study highlights the role of prepregnancy care and the importance of close monitoring during pregnancy and identifies those patients at the highest risk for retinopathy progression (Journal of Diabetes Research)
FDA approves new treatment for diabetic retinopathy in patients with diabetic macular edema
The U.S. Food and Drug Administration expand the approved use for Eylea (aflibercept) injection to treat diabetic retinopathy in patients with diabetic macular edema
Social deprivation as a risk factor for late presentation of proliferative diabetic retinopathy
In our cohort social deprivation appears to be associated with late presentation of proliferative diabetic retinopathy. Our study supports the need to target these groups to reduce preventable blindness and to identify strategies which overcome barriers to care (Clinical Ophthalmology)
A classification model for predicting eye disease in newly diagnosed people with type 2 diabetes
A classification model using readily available patient information and routine biochemical measures can be used to identify patients at high risk of having retinopathy at the time their diabetes is diagnosed; The model may be used to identify high-risk patients for retinopathy screening (Diabetes Research and Clinical Practice)
Glycosmedia is also available as an App: